SEATTLE, WA / ACCESSWIRE / May 15, 2014 / TapImmune Inc. (TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to announce that the company will be presenting at the 3rd Annual SeeThroughEquity Microcap Investor Conference on May 28th 2014 in New York.
The conference is being held at the Convene Grand Central and runs from 8am to 6pm. The company will present at 2pm. For more information and attendees and sponsors please visit http://www.seethruequity.com/#!upcomingconference/cc6n
TapImmune will be presenting and discussing significant recent company events and outlining 2014 milestones including:
- interim data on it clinical programs in Breast and Ovarian cancer
- Final data on pre-clinical small animal studies in smallpox at Mayo Clinic and decision on advancement to non-human primates and license deal and partnering opportunites.
- Major financing
- Uplisting to NASDAQ in 2014
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements
Glynn Wilson, PH.D.
Chairman & CEO
SOURCE: TapImmune Inc.